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Abstract Amyotrophic lateral sclerosis (ALS) is a devastat-
ing and still untreatable motor neuron disease. Despite the
molecular mechanisms underlying ALS pathogenesis that
are still far from being understood, several studies have sug-
gested the importance of a genetic contribution in both famil-
ial and sporadic forms of the disease. In addition to single-
nucleotide polymorphisms (SNPs), which account for only a
limited number of ALS cases, a consistent number of common
and rare copy number variations (CNVs) have been associated
to ALS. Most of the CNV-based association studies use a
traditional candidate-gene approach that is inadequate for
uncovering the genetic architectures of complex traits like
ALS. The emergent paradigm of “systems biology”may offer
a new perspective to better interpret the wide spectrum of
CNVs in ALS, enabling the characterization of the complex
network of gene products underlying ALS pathogenesis. In
this review, we will explore the landscape of CNVs in ALS,
putting specific emphasis on the functional impact of common
CNVregions and genes consistently associated with increased
risk of developing disease. In addition, we will discuss the
potential contribution of multiple rare CNVs in ALS patho-
genesis, focusing our attention on the complex mechanisms
by which these proteins might impact, individually or in com-
bination, the genetic susceptibi l i ty of ALS. The
comprehensive detection and functional characterization of
common and rare candidate risk CNVs in ALS susceptibility
may bring new pieces into the intricate mosaic of ALS path-
ogenesis, providing interesting and important implications for
a more precise molecular biomarker-assisted diagnosis and
more effective and personalized treatments.
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Background
Amyotrophic lateral sclerosis (ALS) is a devastating
untreatable neurodegenerative disease characterized by the se-
lective degeneration of motor neurons in the brain and spinal
cord, leading to paralysis and death, usually from respiratory
failure, within 3–5 years of onset [1]. The disease exists in two
forms: familial ALS (FALS) and sporadic ALS (SALS).
FALS is a rare monogenic disease that occurs in 5–10% of
cases with an autosomal dominant inheritance and for which
several causal genes have been identified, including SOD1,
ALS2, SETX, SPG11, FUS, VAPB, ANG, TARDBP, FIG4,
OPTN, ATXN2, UBQLN2, PGRN, PFN1, DCTN1, and
C9ORF72 [2]. SALS comprises the majority (90–98%) of
ALS cases and is considered to be a complex multifactorial
disorder, involving multiple pathogenic processes, such as
oxidative stress, protein aggregation, mitochondrial dysfunc-
tion, excitotoxicity, and impaired axonal transport (Fig. 1) [3].
Although there are still missing pieces in the intricate mosaic
of SALS pathogenesis, several studies have recognized the
important contribution of genetic risk factors, usually associ-
ated with incomplete penetrance, and gene-environment inter-
actions for disease susceptibility (Fig. 1).
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The remarkable advances in genome technologies over the
last years have led to huge progress in the understanding of the
genetic mechanisms involved in ALS. The search for patho-
genic variants has been initially focused primarily on varia-
tions at the single-nucleotide polymorphism (SNP) level. In
the last years, several candidate-gene or genome-wide associ-
ation studies (GWAS) have identified multiple SNPs affecting
potentially ALS-associated genes, including VEGFA, ANG,
FGGY, DPP6, ITPR2, KIFAP3, and UNC13A [4–7].
However, the contribution of nucleotide sequence abnormali-
ties in SALS pathogenesis remained unclear, with point mu-
tations in the above genes occurring only rarely.
In addition to SNPs, submicroscopic chromosomal changes,
also known as copy number variations (CNVs), represent a
substantial source of inter-individual genetic variations exerting
important phenotypic effects on the expression and function of
genes and representing one of the major risk factors for various
complex human disorders including ALS [8, 9]. The majority
of existing CNV genotyping studies use a traditional
single-gene approach that, albeit has provided valuable infor-
mation regarding the impact of individual common variants, is
inadequate for uncovering genetic architectures of complex
traits like ALS, often leading to the loss of less-frequently but
potentially functionally relevant CNV-driven gene sets. In this
context, the holistic “systems biology” approach provides a
new perspective in the study of complex disease traits, which
goes beyond the conventional one-gene-at-a-time testing
scheme, and embraces the entire equilibrium of a biological
system undergoing a much more complicated network of mo-
lecular components that in association increase the likelihood of
developing the disease (Fig. 2) [10].
In this review, we will explore the currently known land-
scape of CNVs, putting specific emphasis on CNV-driven
genes that have been consistently associated with an increased
risk of ALS, considering their potential functional impact in
the pathophysiology of the disease. In addition, we will exam-
ine the potential contribution of multiple rare CNVs in ALS
pathogenesis, focusing our attention on the complex mecha-
nisms bywhich these proteins might impact, both individually
or in combination, to the genetic susceptibility of ALS.
Main Text
Copy Number Variations: an Overview
One of the most important scientific discoveries about the
human genome study is that, in addition to nucleotide se-
quence variants such as SNPs, different types of genomic
structural variations contribute significantly to genetic hetero-
geneity [11, 12]. Genomic structural variants include many
different types of chromosomal rearrangement encompassing
both inversions and balanced translocations as well as geno-
mic imbalances commonly referred to as copy number varia-
tions (CNVs).
CNVs are defined as fragments of DNA larger than 1 kb
(variants smaller than 1 kb are termed InDels) presenting un-
balanced rearrangements in comparison to a reference genome
[13–15]. These can be rare (<1%) or common (>5%); de novo
or inherited; and include structural gains (duplication or inser-
tional transpositions), losses (e.g., deletions), or complex
Fig. 1 Schematic representation
of the complex mosaic of ALS
pathogenesis
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rearrangements. In particular, deletions can be heterozygous
(with only one copy missing), homozygous (with both copies
missing), or hemizygous (e.g., X chromosome deletions in
males) [16]. In the case of copy number gains, it is possible
to distinguish duplications (three copies of a genomic region)
from other complex genomic rearrangements, such as homo-
zygous duplications (four copies with two copies on each
allele), triplications (four copies with three copies on one al-
lele and one copy on the other allele), and quadruplications
(five copies) [17]. Although single-copy deletions and gains
of one or two extra copies of DNA are common, the complete
genetic loss of both alleles and more extensive amplification
of specific DNA regions have been only rarely described.
Methodological Approaches for CNVs Detection
and Analysis
The conventional karyotyping techniques typically detect chro-
mosomal aberrations greater than 5–10 Mb ruling out other
forms of submicroscopic CNVs. The recent advent of
genome-wide approaches has driven much of the research on
CNVs facilitating their identification and characterization at
much higher resolution than hitherto. Several methods for de-
tecting CNVs are currently available and can be categorized into
genome-wide and targeted detection approaches (Fig. 3) [18].
Genome-wide approaches permit to scan the entire genome
for CNVs detection and include microarray-based
(array-comparative genomic hybridization (CGH) and SNP
array) and next-generation sequencing (NGS)-based analyses
(Fig. 3). Originally, array-CGH included only a few hundreds
of thousands of large-insert clones (known as bacterial artifi-
cial chromosomes (BACs)) with a relatively low spatial reso-
lution (typically >5–10 Mb) and required a relatively large
volume of DNA [19]. Subsequently, high-density
oligo-synthesized arrays have been developed, offering a
much higher resolution with a more accurate definition of
CNV boundaries [20]. In addition to array-CGH,
high-density SNP genotyping arrays have also gained interest
for CNV detection and analysis, mainly due to their dual role
for both SNP- and CNV-based association studies [21].
Fig. 2 The systems biology
approach: from integration of
large-scale Bomics^ data to
personalized medicine practice
Mol Neurobiol
Although microarray technologies currently represent the
most powerful available method to identify CNVs, they can-
not detect short CNVs. The advent of NGS technologies has
allowed to overcome this limitation, offering the possibility to
reveal much smaller CNVs (<10 kb) and define CNV
breakpoints at the single nucleotide level [22].
Despite genome-wide approaches providing reliable and
efficient methodological insights for large-scale association
analyses, other CNV detection methods are preferably used
for the validation process as well as phenotype/genotype cor-
relation and clinical translation of a relatively small set of
known CNVs. These “targeted methods” include fluorescence
in situ hybridization (FISH), quantitative polymerase chain
reaction (qPCR), and multiplex ligation-dependent probe am-
plification (MLPA) (Fig. 3) [14]. FISH has been the first mo-
lecular method able to detect submicroscopic genomic CNVs,
but it is a time-consuming method that requires prior knowl-
edge of the regions of interest, not allowing for genome-wide
analyses [23]. qPCR is an efficient method for screening
CNV-targeted genomic regions. However, this technique does
not allow the simultaneous amplification and quantification of
a large number of targets in a single reaction. MLPA is an
alternative targeted PCR-based approach that allows simulta-
neous analysis of multiple targets (up to 40 targets) with one
primer pair, reducing the probability of obtaining spurious
qPCR results due to different reaction conditions [24].
The Origin of CNVs and their Functional Impact
in the Human Genome
Significant progress has beenmade to date in the field of CNV
detection and analysis; however, much remains to be
investigated about mechanisms that cause CNVs and their
functional consequences. CNVs can arise from a multitude
of molecular mechanisms (e.g., non-allelic homologous re-
combination between repeated elements, non-homologous
DNA repair mechanisms, replication errors, and transposable
element-mediated mechanisms) and can involve one or mul-
tiple genes as well as regulatory regions [25, 26]. Based on
their size and the genomic region in which they occur, CNVs
can affect gene functions in a variety of ways: by disrupting
gene coding sequences (for example by deleting or inserting
exonic sequences), producing novel fusion genes and splice
variants, as well as by affecting regulatory elements and other
functional regions, thus perturbing the assembly of the tran-
scription machinery. These variations at the genomic level
may result in alterations at the protein level, leading to
eliminated/reduced or increased expression levels or
interrupted coding sequences that cause the formation of trun-
cated proteins with altered functions. Moreover, disruption of
the regions including transcription regulatory elements and
enhancers can also result in long-distance effects (even up to
1 Mb) by altering the expression of genes in neighboring
chromosomal regions [27].
Changes in copy number are extremely frequent in the
human genome (12–15%) representing one of the most prev-
alent types of genetic variations [11]. Approximately, more
than 66,000 CNVs and 34,000 InDels were identified in var-
ious populations and cataloged in the Database of Genomic
Variants (DGV) (http://dgv.tcag.ca/dgv/app), a public and
comprehensive catalog of human CNVs and genomic
structural variations identified in healthy controls [8, 28].
While the majority represents benign polymorphic variants,
increasing numbers of CNVs are associated with a higher
Fig. 3 The most widely used
methods for genome-wide and
targeted CNVs detection and
analysis
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risk of developing various types of inherited Mendelian and
complex disease traits, including neurological disorders [29,
30]. Several recent studies, in fact, have supported the role of
CNVs in causing or influencing the susceptibility to many
neurological and developmental conditions, such as
Charcot–Marie–Tooth neuropathy [31], autism [32],
schizophrenia [33], epilepsy [34], Crohn’s disease [35], and
neurodegenerative disorders, including Alzheimer’s,
Parkinson’s and ALS [36, 37].
Copy Number Variations in ALS
Recent advances in genomic technologies have led to huge
progress in understanding the genetic mechanisms underlying
ALS, allowing the identification and characterization of novel
genetic susceptibility loci, such as CNVs [38]. Various studies
have, in fact, highlighted the possible association between
common and rare candidate CNV-driven genes or genomic
regions and increased risk of developing ALS (Table 1).
In the following paragraphs, we review the most plausible
candidate CNV loci that have been consistently associated
with ALS, highlighting their potential functional impact in
the pathophysiology of the disease (Tables 1 and 2 and Fig. 4).
Survival Motor Neuron
Among candidate genes that may modulate susceptibility and
disease course in ALS, a great deal of attention has been given
to the survival motor neuron (SMN) gene. It maps in a highly
duplicated region of chromosome 5 (5q13.3) and is present in
two homologous copies: a telomeric copy called SMN1 and a
centromeric copy called SMN2 that produces approximated
only 20% of full-length transcripts coding for SMN [39].
This is a housekeeping protein that is essential for the efficient
assembly and regeneration of spliceosomal small nuclear ri-
bonucleoproteins (snRNP) in various human cell types, in-
cluding the axons of spinal motor neurons, exerting important
effects in protein translation, as well as in the mitochondria
and cytoskeleton maturation and synaptic transmission regu-
lation (Table 2 and Fig. 4) [40].
Aberrant CNVs in SMNs result in a defective protein, lead-
ing to deficits in snRNP assembly, disruption of normal cel-
lular RNA metabolism, and motor neuron degeneration [41].
Homozygous deletions of SMN1 are responsible for the path-
ogenesis of spinal muscular atrophy (SMA), an autosomal
recessive motor neuron disease characterized by lower motor
neuron loss and muscle atrophy, while SMN2 copy numbers
seem to modulate the severity of the SMA phenotype and
survival [42].
Because of the phenotypic similarities between SMA
and ALS, various studies have focused on the possible
association between copy number abnormalities in SMN
genes and ALS, but controversial results have been
obtained (Table 1). Indeed, although several studies
have demonstrated that high or low SMN1 copy number
together with the absence of SMN2 increased risk of
developing ALS [43–48], others have not found any
significant association [49–51]. These apparently contra-
dictory data, at least in part, may be due to the use of
inadequate size populations and different assays used to
assess CNVs in the SMN genes. Similar conflicting re-
sults were also observed at the SMN protein level.
Indeed, both low and high levels of SMN production
seem related to the risk of ALS. Upregulated expression
of SMN genes was recently found in the motor cortex
of SALS patients, supporting the evidence that overex-
pression of SMN protein may be toxic for motor neu-
rons [52, 53]. Decreased levels of SMN result, instead,
in a reduction of its chaperone-like activity against mu-
tant SOD1-mediated toxicity in vitro, contributing to
increase-free radical injury and oxidative stress, two
well-established features of ALS [54]. In support of this
theory, it has been demonstrated that an increase in the
levels of SMN improved motor functions and delayed
motor neuron loss in different cellular and animal
models of ALS [55, 56].
Further evidence for the contribution of SMN signaling in
ALS pathogenesis is based on the observation that SMN and
some ALS-associated proteins share common biochemical
pathways. This is the case, for example, of FUS and
TDP-43, two gene-encoding proteins extensively associated
with both sporadic and familial ALS that colocalize with SMN
in subnuclear organelles known as gems (gemini of Cajal
bodies). ALS-related mutations in these genes seem to con-
tribute to motor neuron dysfunctions also by reducing the
localization of SMN to axons with the consequent disruption
of the SMN-mediated assembly and integrity of the splicing
machinery [57–59].
Considering its potential impact on ALS pathogenesis, sev-
eral studies have investigated the role of SMN as a pharma-
cological target in ALS. To this regard, the systemic adminis-
tration of valproate (VPA), a drug able to increase the SMN
levels in the SNC through an epigenetic mechanism, has
shown neuroprotective effects both on SMA and ALS patients
[60].
In addition to alterations in the activity of SMN complex,
aberrant copy numbers in the SMN genes might confer sus-
ceptibility for ALS also through SMN-independent mecha-
nisms, acting, for example, as markers of linkage disequilib-
rium with other ALS susceptibility loci, such as the neuronal
apoptosis inhibitory protein (NAIP) gene. A more detailed and
accurate molecular genetic investigation of the SMN gene re-
gion could reveal additional genetic variants with potential
relevance for ALS, providing new insights into the common
pathogenic mechanisms underlyingALS and other motor neu-
ron diseases [61].
Mol Neurobiol
Table 1 Characteristics of the most significant CNVs and overlapped genes from different genome-wide studies showing association with ALS
Chr Position start–end
(CNV length)
CNV type CNV detection
method
ALS patients Controls Overlapped genes¥ Reference












Deletion SNP array 3
(no. cases = 12)
0
(no. controls = 24)
Intron of FMN2 [138]
1 52,994,160–53,423,907 Gain BAC array
(aCGH validation)
1








3 2,944,819–2,947,844 Gain SNP array 2
(no. cases = 32)
0
(no. controls = 26
)
Intron of CNTN4 [138, 165]



















Deletion SNP array 1
(no. cases = 12)
0
(no. controls = 24)
Promoter of CHL1 [138]
3 Not reported
(53,562 bp)
Loss SNP array 1
(no. cases = 12)
0
(no. controls = 24)
52% of DHX30 (+ promoter),
9% of SMARCC1 (+ promoter)
[138]
3 60,357,746–60,604,845 Gain BAC array
(aCGH validation)
1

















Loss SNP array 1
(no. cases = 12)
0
(no. controls = 24)
3% of RPS3A (+ promoter),




Deletion SNP array 1
(no. cases = 12)
0
(no. controls = 24)
Promoter of UGT8 [138]



























6 109,034,609–109,074,882 Gain SNP array 1
(no. cases = 32)
0
(no. controls = 26
)
Intron of FOXO3 [99]
6 123,569,244–124,360,902 Gain BAC array
(aCGH validation)
1

















































8 73,609,541–73,629,084 Gain SNP array 1
(no. cases = 32)
0
(no. controls = 26
)
Region overlaps with 86.50%
of KCNB2
[99]
8 144,686,338–144,765,210 Loss and
gain





CNV type CNV detection
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PHRF1, IRF7, MUPCDH, SCT,
DRD4, DEAF1
[110]



















Deletion SNP array 5
(no. cases = 12)
0
(no. controls = 24)
None [138]










(31 dup, 3 del)
(no. controls =
8731)
TUBGCP5, CYFIP1, NIPA2, NIPA1 [84]
15 Not reported
(5695 bp)
Deletion SNP array 2
(no. cases = 12)
0
(no. controls = 24)
None [138]
15 19,818,989–20,084,080 Deletion SNP array 2




LOC650137 (+), OR4M2 (+),
OR4N4 (+)
[99]







16 87,957,353–87,971,263 Gain SNP array 2
(no. cases = 32)
0
(no. controls = 26)
Intron of ANKRD11 [99]





















Gain SNP array 1
(no. cases = 12)
0
(no. controls = 24)























19 Not reported Loss SNP array 2
(no. cases = 12)
0
(no. controls = 24)
Intron of ZFP14 [138]
22 23,696,411–24,240,667 Loss and
gain
SNP array 10


















22 29,489,697–29,489,738 Deletion SSCP 5 2 NEFH [68]
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Neurofilament Heavy Subunit
Neurofilaments (NFs) are the most prominent cytoskeletal
components in neurons. They are composed of a globular
head, α-helical rod region, and a globular tail and are
expressed under three different neuron-specific subunits with
different molecular weights: light (NEFL), medium (NEFM),
and heavy (NEFH). NFs, together with microtubules and mi-
crofilaments, form part of the slow axonal transport and con-
tribute to the formation andmaintenance of the neuronal struc-
ture (Table 2 and Fig. 4) [62].
Although the role of NFs in ALS is not yet fully clarified,
dysregulated expression and point mutations of NFs have
been reported in human and animal models of ALS [52, 63,
64]. The principal pathogenic mechanism of these variations
seems to be related to defects of the normal NFs assembling
and phosphorylation. These alterations, in addition to dys-
function of the ubiquitine-proteasome system, may cause
changes in the cross-linking properties of NFs, resulting in
the aberrant accumulation of these proteins in motor neurons,
which represents an established pathologic hallmark of ALS
[65, 66].
Several studies have investigated the role of NF structural
chromosomal alterations in ALS (Table 1). Deletions in
NEFL, accompanied by a concomitant altered expression of
NEFH and NEFM in the cell bodies and axons of motor neu-
rons, have been associated with a significant delay of the
disease onset and progression in ALS animal models [67].
In addition, point mutations (C2232T and C2414A) were also
found in the short allele of NEFH, suggesting that these may
act as markers for deletion mutants [68].
Significant associations were also established between the
sporadic form of ALS and deletions in the C-terminal tail of
NEFH [68]. This region is composed of a unique functional
domain consisting of 43–45 repeat motifs of the amino acids
lysine-serine-proline (KSP) [69]. The phosphorylation of
these motifs in the C-terminal tail allows NEFH to interact
with other cytoskeletal components (e.g., microtubule-
associated proteins), regulating the interfilament spacing and
thereby the axonal caliber. Deletions of the NEFH KSP
domain have been detected in SALS patients as well as in
some patients with a FALS pedigree, even if it was not yet
determined whether the variant segregates with the disease or
not [70, 71]. Interestingly, loss of a KSP motif, or multiples of
this, seems to affect a recognition sequence for the neurofila-
ment kinase CDK5, suggesting that deletions at this level may
result in aberrant interactions of NEFH with other cytoskeletal
elements, leading to axonal and cytoskeleton integrity destruc-
tion and motor neuron degeneration.
Isopentenyl Diphosphate Isomerase
Although the exact association between alterations in
lipid metabolism and ALS remains unknown, there are
several evidence of possible involvement of cholesterol
and other lipids in the disease pathogenesis. Decreased
cholesterol levels as well as dysfunctions in lipids trans-
port and metabolism have been found in both human
and ALS animal models while increasing dietary lipid
content appears to be associated with neuroprotective
effects [72–75].
Among proteins involved in the lipid metabolism is the
isopentenyl diphosphate isomerase (IDI), a cytoplasmic en-
zyme belonging to the mevalonate pathway that plays an es-
sential role in the biosynthesis of cholesterol and other lipo-
philic molecules (Table 2 and Fig. 4). IDI has two isoforms in
humans, IDI1 and IDI2 that are encoded by two tandemly
duplicated genes [76, 77].
Several studies support the role the mevalonate pathway
and IDIs in the pa thogenes is of sporadic ALS.
Downregulated expression of IDI1 was recently found in the




CNV type CNV detection
method





X 139,400,576–telomere Deletion BAC array
(aCGH validation)
1




>100 (No ALS candidate genes) [165]
X 139,526,743–139,942,807 Gain BAC array
(aCGH validation)
1





The table shows the most significant CNV loci and relative genes that partially or completely fall within them. Chromosomal positions are referred to the
human reference genome assembly corresponding to each individual study: in particular [115], [40], and [81] refer to the NCBI reference sequence build
36, [98] refers to the build 38 and [41] refers to UCSCGenome Browser, May 2004 Freeze. In the case of [71], the authors described deletion coordinates
by using the numbering of the published sequence by Lees et al. EMBO J. 1988. Genes that may be reasonable ALS candidates are in bold
Chr Chromosome, SSCP single-strand conformation polymorphism analysis, Loss heterozygous deletion, Deletion homozygous deletion
¥Gene symbols correspond to the NCBI Refseq names
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Table 2 Genes overlapped with CNV loci with a potential relevance for ALS susceptibility
Gene Description Chromosomal
location















isomerase 1 and 2
10p15.3 Cholesterol biosynthesis Gain
DPP6 Dipeptidyl-peptidase 6 7q36.2 Regulation of neuronal action potential, regulation of potassium ion






15q11.2 Transmembrane transport Loss
EPHA3 Ephrin type-A receptor 3 3p11.2 Axon guidance, cell adhesion, cell migration, signaling, cytoskeleton
organization
Loss
AATK Apoptosis-associated tyrosine kinase 17q25.3 Brain development, regulation of axon extension, neuron apoptotic
process
Gain
BAIAP2 BAI1-associated protein 2 17q25 G protein coupled receptor signaling pathway, neurotransmitter
secretion
Gain
CHMP6 Charged multivesicular body protein 6 17q25.3 Endosomal transport, membrane organization, nucleus organization,
protein transport
Gain
IGFALS Insulin-like growth factor binding
protein acid labile subunit
16p13.3 Cell adhesion, cellular protein metabolic process, signal transduction Gain
CACNA1H Calcium channel, voltage-dependent, T
type, alpha 1H subunit
16p13.3 Axon guidance, calcium ion import, membrane depolarization during
action potential, muscle contraction, regulation of membrane
potential
Gain
MAPK8IP3 Mitogen-activated protein kinase 8
interacting protein 3
16p13.3 JNK cascade, axon guidance, neuron projection development,
positive regulation of neuron differentiation, regulation of gene
expression, vesicle-mediated transport
Gain
BAIAP3 BAI1-associated protein 3 16p13.3 G-protein coupled receptor signaling pathway, neurotransmitter
secretion
Gain
UBE2I Ubiquitin-conjugating enzyme E2I 16p13.3 DNA repair, cell cycle, cell division, cellular protein metabolic
process, chromosome segregation, nucleotide-excision repair,
post-translational protein modification, protein ubiquitination
Gain
SPSB3 splA/ryanodine receptor domain and
SOCS box containing 3
16p13.3 Intracellular signal transduction, protein ubiquitination Gain
KCNIP4 Kv channel interacting protein 4 4p15.32 Potassium ion transport Deletion
KCNB2 Potassium channel, voltage gated Shab
related subfamily B, member 2
8q13.2 Potassium ion transport, synaptic transmission Gain
KCNQ5 Potassium channel, voltage gated
KQT-like subfamily Q, member 5
6q14 Potassium ion transport, synaptic transmission Loss
GSDMD Gasdermin D 8q24.3 Cellular response to extracellular stimulus Gain &
Loss
GRIK1 Glutamate receptor, ionotropic, kainate
1
21q22.11 Central nervous system development, glutamate receptor signaling
pathway, ion transport, membrane depolarization, regulation of
synaptic transmission, regulation of synaptic plasticity
Loss
GRIK2 Glutamate receptor, ionotropic, kainate
2
6q16.3 Central nervous system development, glutamate receptor signaling
pathway, ion transport, membrane depolarization, regulation of
synaptic transmission, regulation of synaptic plasticity, regulation
of neuron apoptotic process, regulation of JNK cascade
Gain
EEF1D Eukaryotic translation elongation factor
1 delta (guanine nucleotide exchange
protein)
8q24.3 Cellular protein metabolic process, gene expression, mRNA
transcription, positive regulation of I-kappaB kinase/NF-kappaB
signaling, regulation of cell death, signal transduction
Gain &
Loss
ATXN1 Ataxin 1 6p23 RNA processing, excitatory postsynaptic potential, regulation of
transcription, regulation of glial cell proliferation
Loss
ATXN3L Ataxin 3-like Xp22.2 Cellular response to misfolded protein, protein deubiquitination,
regulation of transcription
Gain
SLC1A7 Solute carrier family 1 (glutamate
transporter), member 7
1p32.3 L-glutamate transmembrane transport, neurotransmitter secretion,
synaptic transmission
Gain
TRDN Triadin 6q22.31 Gain
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Moreover, a segmental copy number gain, encompassing the
IDI1/IDI2 gene region on 10p15.3 subtelomere, was found in
SALS patients. This duplication leads to the disruption of the
genetic composition and reduction of the IDI1 expression
(Table 1) [78]. The association between IDI1/IDI2 copy num-
ber alterations and the sporadic form of ALS may be ex-
plained by the instability of this genomic region that contains
multiple low-copy repeats in a small region of the genome.
These segmental duplications can arise from an unequal
crossing-over or end-joining events, suggesting the possibility
that de novo CNVs may occur [79]. Further investigation
about the function of IDI1/IDI2 in motor neurons may allow
to obtain new insights into the pathogenesis of SALS and to
identify also novel promising therapeutic targets for this
disease.
Dipeptidyl-Peptidase 6
Dipeptidyl aminopeptidase-like protein 6 (DPP6) is a member
of the prolyl oligopeptidase family of serine proteases. It is
predominantly expressed in the central nervous system which
modulates the function and expression of potassium channels
as well as excitability at the glutamatergic synapse (Table 2
and Fig. 4).
Although the role of DPP6 in ALS pathogenesis remains
unclear, genetic variations in DPP6 have been identified as
potential risk factors for different human diseases, including
ALS [6, 80–82]. Several genome-wide studies, in fact, have
reported an association between an SNP (rs10260404) in
DPP6 and ALS susceptibility and increased expression of




GO Processes Associated Type of
CNV
Cellular calcium ion homeostasis, cytoplasmic microtubule
organization, endoplasmic reticulum membrane organization,
muscle contraction, transmembrane transport
CPLX1 Complexin 1 4p16.3 Exocytosis, glutamate secretion, regulation of exocytosis, synaptic
transmission, synaptic vesicle exocytosis, transport
Gain
ANKRD11 Ankyrin repeat domain 11 16q24.3 Multicellular organism growth, tissue homeostasis Gain
PPP1R13B Protein phosphatase 1 regulatory
subunit 13B
14q32.33 Apoptotic process Gain
FOXO3 Forkhead box O3 6q21 DNA damage response, apoptotic process, cell differentiation,
cellular response to oxidative stress, epidermal growth factor
receptor signaling pathway, immune response, regulation of
neuron differentiation, transcription, tumor necrosis
factor-mediated signaling pathway
Gain
HFE Hemochromatosis 6p21.3 Antigen processing and presentation, immune response, ion
transport, regulation of proteasomal ubiquitin-dependent protein
catabolic process, regulation of receptor activity, positive
regulation of gene expression, regulation of protein binding,
transport
Gain
GGTLC2 Gamma-glutamyltransferase light chain
2
22q11.22 Glutathione metabolic process Loss
ATG7 Autophagy related 7 3p25.3 Autophagy, cellular homeostasis, cellular protein modification
process, cellular response to hyperoxia, central nervous system
neuron axonogenesis, cerebral cortex development, membrane
organization, mitochondrion organization, regulation of apoptotic
process, protein transport, protein ubiquitination
Loss
ANXA5 Annexin A5 4q27 Calcium ion transmembrane transport, regulation of apoptotic
process, signal transduction
Loss
GEMIN6 Gem nuclear organelle-associated
protein 6
2p22.1 Gene expression, mRNA processing, mRNA splicing Loss
MTMR7 Myotubularin-related protein 7 8p22 Dephosphorylation Loss
ACYP2 Acylphosphatase 2, muscle type 2p16.2 Phosphate-containing compound metabolic process Loss
ZFP14 ZFP14 zinc finger protein 19q13.12 Regulation of transcription Loss
FMN2 Formin 2 1q43 Actin filament assembly, cellular response to DNA damage stimulus,
cellular response to hypoxia, intracellular signal transduction,
intracellular transport, multicellular organismal development,
regulation of apoptotic process, protein transport, vesicle-mediated
transport
Deletion
Loss heterozygous deletion; Deletion homozygous deletion
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83]. In addition, deletions and duplications affecting DPP6
were also found in some cases of ALS (Table 1) [84]. These
copy number aberrations occur mainly at the 5′ end of the
gene, a known CNVregion flanked by segmental duplications
mediating genomic rearrangements [85]. The functional im-
pact of these genomic aberrations seems to involve the gener-
ation of altered or truncated transcripts as well as the disrup-
tion of regulatory elements in this region that may alter gene
expression. Further investigations are necessary to better clar-
ify the function of DPP6 in the nervous system and its poten-
tial role in ALS susceptibility.
Non-imprinted in Prader-Willi/Angelman Syndrome
Non-imprinted in Prader–Willi/Angelman syndrome (NIPA1,
also known as SPG6) is an inhibitor of bone morphogenic
protein signaling, one pathway that plays an important role
in the formation, maintenance, and function of synapses as
well as in transmembrane transport (Table 2 and Fig. 4).
Despite mutations in NIPA1 not being directly linked to ALS
pathogenesis, they are known to cause hereditary spastic para-
plegia (HSP) type 6, a neurodegenerative disease character-
ized by the selective degeneration of upper motor neurons
[86]. Although ALS and HSP are clinically different, they
share important clinical features, including selective motor
neuron degeneration. Mutations in some genes causing vari-
ous forms of HSP, such as SPAST and SPG11, were also asso-
ciated with ALS phenotype [87]. In particular, SPG11 encodes
spatacsin, another inhibitor of bone morphogenic protein sig-
naling, supporting the involvement of this pathway in motor
neuron degeneration and pathogenesis of both ALS and HSP.
NIPA1 polyalanine repeat expansions have been identified
as potential risk factors for ALS and appear involved in the
modulation of the disease course. Moreover, several CNVs
affecting NIPA1 were also found in SALS patients (Table 1)
[84, 88]. In particular, these copy number alterations affect a
known CNV region of chromosome 15 (15q11.2) flanked by
segmental duplications. While duplications in this region do
not seem to contribute to ALS susceptibility, deletions over-
lapping four adjacent genes, including NIPA1, showed a
strong statistical association (Table 1) [84]. Recently, CNVs
in the NIPA1 region have been also associated with other neu-
rological diseases, including schizophrenia and epilepsy, sug-
gesting that NIPA1 and other genes inside the same
CNV-driven region, in association with other risk factors,
may concur to cause these different pathologic phenotypes
[89].
Ephrin Type-A Receptor 3
Ephrin receptors (Ephs) represent the largest known subfamily
of tyrosine kinase receptors. Ephrin receptors and their ligands
are involved in a variety of important functions, including
axonal outgrowth, cytoskeletal structure development, neuro-
nal connectivity, neuronal apoptosis, synaptic maturation, and
plasticity (Table 2 and Fig. 4) [90, 91].
Alterations in the expression or function of ephrins and
their receptors induce pathological changes in the motor neu-
ron circuitry, contributing to the initiation and progression of
ALS pathogenesis [92]. In accordance with this theory,
deregulated expression of ephrins and their receptors was
found in the motor cortex and spinal cord of SALS patients
[3, 93] and several SNPs affecting Eph/ephrin genes have
been associated with ALS susceptibility [94]. It is of interest
to note that some of these alterations often result in beneficial
effects. Indeed, loss-of-function mutations in EPHA4 or com-
plete knockdown of this gene have shown to rescue and pro-
long survival in ALS animal models [95]. In addition, a
Fig. 4 A representative illustration showing the functional correlation
between ALS-associated CNV-affected genes and their biological
processes. Interaction map represents the most promising candidate
genes overlapping CNVs that have been consistently associated with
ALS, grouped on the basis of the main biological processes associated
with them. The map was created using the MetaCore Pathway Map
Creator tool (GeneGo). Genes associated with CNV gain regions are
labeled with red dots while genes associated with homozygous or
heterozygous deleted CNVs are labeled with blue dots. The
Bcheckerboard^ color indicates genes displayed both CNV gains and
losses. Detailed information about genes depicted in the figure and
related biological processes are reported in Table 2. A detailed legend
for the network objects is shown in Supplementary Fig. 1
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heterozygous deletion of EPHA3 was found significantly
higher in controls as compared to ALS patients, supporting a
potential protective role of this variant against the risk of de-
veloping ALS (Table 1) [96]. All these evidence support the
importance of Eph/ephrin signaling in modulating the vulner-
ability of motor neurons to axonal degeneration, highlighting
the necessity to further investigate this protein family as prom-
ising therapeutic candidates for ALS.
Mitochondrial DNA Genes
Impaired mitochondrial bioenergetics function plays an im-
portant role in several neurodegenerative diseases, including
ALS. In particular, dysfunctions in mitochondria result in a
reduction in bioenergetics efficiency, increasing the risk of
neuronal death when energy demands exceed cellular energy
production [97, 98].
One of the genes primarily involved in oxidative phosphor-
ylation encodes cytochrome c oxidase (CO), the terminal
component of the mitochondrial respiratory chain that trans-
fers electrons from reduced cytochrome c to molecular oxy-
gen. CO is a multiheteromeric enzyme composed of 13 pro-
tein subunits, some of which coded by mitochondrial DNA
(mtDNA) genes [99, 100]. Reduced levels of CO histochem-
ical activity as well as mutations and heterozygous deletions
in mtDNA genes encoding some CO subunits (such as CO3
and COX7C) have been detected in patients with ALS pheno-
type, contributing to reduce bioenergetic functions observed
in ALS motor neurons (Fig. 4) [101–104].
In addition to genetic variations of mtDNA CO genes, de-
letions in other mtDNA genes were found in substantia nigra
neurons, where it seems to cause cellular respiration deficits,
reduced capacity to modulate synaptic activity, and swings in
cytosolic calcium levels as well as reduced capacity to survive
to excitotoxic stresses [105, 106]. Although it is not yet fully
clarified how these mtDNA deletions arise, their origin may
involve failures in the mitochondrial biogenesis programs as
well as genetic, epigenetic, or post-translational causes (or
their combinations) [107, 108]. Similar chromosomal rear-
rangements have been also observed in ALS phenotype.
Indeed, high abundances of deletions involving ND2 and
ND4, two mtDNA genes that code for NADH-ubiquinone
oxidoreductase, an essential respiratory protein complex, were
found in the spinal cord of ALS patients, supporting the con-
cept that some motor neurons in ALS may die because of a
deficit in the mitochondrial ATP production and cellular ener-
gy metabolism (Fig. 4) [102].
It is interesting to note that while some ALS patients were
characterized by an accumulation of mtDNA deletions, other
ALS cases showed abundant mtDNA copy numbers and rel-
atively low levels of deletions. This observation is corroborat-
ed by our previous work that described a coordinated decrease
of several gene-encoding proteins involved in the oxidative
phosphorylation pathway only in a specific subgroup of SALS
patients, sustaining the existence of a molecular heterogeneity
in ALS patients [52]. Based on these results, it is evident that
mitochondria-targeted therapies, aimed to provide and/or ex-
press intact mtDNA inmotor neurons, may represent a helpful
strategy for the management of bioenergetics defects in spe-
cific subgroups of ALS patients [109].
Multiple Rare CNVs: Assessing their Role
through a System Biology Approach
Despite their importance in deciphering the genetic cause un-
derlying ALS, common CNVs account for only a relatively
small fraction of the genetic variation, while the contribution
of less frequent but potentially functionally important variants
is not yet fully elucidated.
Recent advances in high-throughput genomic technologies
enabled the identification of a large number of rare and novel
ALS-specific CNV loci, which were found in ALS patients
but absent or extremely rare in individual controls of each
study and/or in >2500 controls present in DGV (Table 1 and
Supplementary Table 1) [110, 111]. However, no significant
association was found between these rare variants and the risk
of developing ALS. This may be mainly due to the effect size
of most of these variants that is too small to be detected by
using the traditional statistical methods. In addition, currently,
the majority of genome-wide CNV studies typically apply
a single-gene or single-variant approach, focusing their
attention on the identification of a restricted list of poten-
tial candidates, previously implicated in the disease, with-
out taking into account the potential joint impact of these
rare variants in the etiopathogenesis of ALS [112]. To this
regard, the new systems biology perspective may represent
a powerful tool to overcome these limitations, enabling to
characterize, in a comprehensive or high-throughput man-
ner, the collective effects of these variants that, both indi-
vidually or in combination, can contribute to increase the
likelihood of developing ALS (Fig. 2).
Investigating the potential functional role of rare
ALS-related CNVs, it emerges that, albeit these variants are
individually rare, the target set of genes and related products
may be annotated to one or more common biochemical path-
ways relevant to ALS pathogenesis, including signal transduc-
tion (p value = 5.32 E−06), cell adhesion (p value = 4.67 E−05),
ion transport (p value = 3.67 E−06), and messenger RNA
(mRNA) processing (p value = 3.29 E−04) (Table 2 and
Figs. 4 and 5). Moreover, many of these genes show a func-
tional correlation also with the most known causative ALS
genes (e.g., SOD1, ALS2, SETX, FUS, TARDBP), supporting
the evidence that multiple common and rare CNVs may exert
their pathogenic effect by different multifactorial combina-
tions, jointly contributing to the genetic susceptibility of
ALS (Fig. 6). Interestingly, some of the genes affected by rare
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CNVs encode proteins that are differentially expressed in mo-
tor cortex of SALS patients, sustaining the theory that the
genomic structural variants frequently affect the transcription-
al regulation [52]. Below, we provide a brief description of the
most plausible candidate genes affected by rare ALS-related
CNVs in the light of the main biological processes in which
are involved, in order to investigate their contribution in ALS
pathogenesis and their relevance as potential diagnostic bio-
markers (Fig. 4, Tables 1 and 2 and Supplementary Table 1).
Regulation of Synaptic Transmission and Neuronal Action
Potential
Neurons are physically connected to each other to form exten-
sive neural networks; the synaptic transmission is the process
by which information rapidly flows in neuronal networks.
This is essential for maintaining normal brain function as well
as muscle tone and muscle movements coordination [113].
The disruption of the synaptic stability result in a disruption
of neuronal circuits that represents almost certainly one of the
major underlying causes of many neurologic diseases, includ-
ing ALS, Parkinson’s and Alzheimer’s disease [114–116].
Multiple GWAS studies have described ALS-specific gains
and losses in several genes encoding proteins involved in syn-
aptic transmission and the regulation of neuronal action po-
tential (KCNIP4, KCNB2, KCNQ5, GRIK1, GRIK2, ATXN1,
BAIAP2, CPLX1, CACNA1H, SLC1A7) (Tables 1 and 2 and
Supplementary Table 1) [110, 117].
Different CNVs in some genes that code for potassium
and calcium channels (KCNIP4, KCNB2, KCNQ5,
CACNA1H) were found in ALS patients and seem to have
a particular interest in the deciphering the genetic cause of
ALS (Tables 1 and 2 and Fig. 4). In fact, alterations in the
homeostasis and signaling pathways of these ions seem to
be responsible for some important toxic pathways under-
lying ALS, such as oxidative stress, mitochondrial dys-
function, and neuroinflammation [118]. In particular, an
autoimmune attack on potassium channels has been iden-
tified as a possible risk factor for ALS and alterations in
other potassium channel-related genes (e.g., DPP6) were
Fig. 5 The functional enrichment analysis of the most plausible
candidate genes overlapping ALS-specific CNV loci reveals biological
processes relevant to ALS pathogenesis. a Representation of the top 10
most significantly enriched (p value <0.05) canonical GO biological
processes associated with genes significantly enriched in rare and novel
ALS-specific copy number changes (not reported in controls of each of
the individual studies and/or in >2500 controls present in DGV). The
analysis was performed using the Gene Ontology and KEGG databases
and the list is arranged in descending order with the most significant GO
biological processes at the top. Detailed information about the entire list
of genes affected by ALS-specific CNV loci are reported in
Supplementary Table 1. b GO term pie chart of the top 10 enriched
(p < 0.05) BBiological processes^ for genes overlapping ALS-specific
CNV loci. GO terms or biological features of candidate CNV-affected
genes and the percentage of genes represented in each category are
indicated
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found in several cases of ALS [119]. Moreover,
deregulated expression of multiple genes encoding
calcium and potassium channels were also found in motor
cortex of SALS patients [52].
Fig. 6 Functional network of known and predicted interactions between
proteins encoded by genes affected by rare ALS-specific CNV loci and
the most known causative ALS genes. The network was produced by the
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING)
v10 (http://string-db.org/) using default settings. Proteins are
represented by spheres. Lines linking proteins indicate evidence for
interactions: a red line indicates the presence of gene fusion (genes that
are sometimes fused into single open reading frames); a green line gene
neighborhood (genes that reside within 300 bp on the same strand in the
genome); a blue line co-occurrence (gene families whose occurrence
patterns across genomes show similarities); a purple line experimental
evidence (interaction extracted from protein-protein interaction
databases); a yellow line text mining (interaction extracted from
scientific literature); a light blue line database (interaction extracted
from curated databases); a black line co-expression (proteins whose
genes are co-expressed in the same or in other species)
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Changes in copy number and in the expression levels of
genes encoding glutamate ionotropic receptors (GRIK1,
GRIK2) were identified in several cases of ALS (Table 2 and
Fig. 4) [52, 120]. Glutamate receptors mediate fast excitatory
synaptic transmission in the central nervous system and their
excessive stimulation as well as deregulations in their expres-
sion and activity are responsible for excitotoxicity, a phenom-
enon that has been regarded as one firm mechanism implicat-
ed in both acute and chronic neurodegenerative diseases, in-
cluding ALS [120]. A copy number gain in SLC1A7 (also
known as EAAT5), a gene encoding a member of the gluta-
mate transporter family, was found in a case of ALS but not in
controls or DGV. Altered expression of this gene was found in
the brains of patients with both familial and sporadic forms of
ALS, supporting the role of an aberrant glutamate signaling in
ALS pathogenesis (Table 2, Fig. 4, and Supplementary
Table 1) [121].
Deletions in ATXN1 and a duplication of the related gene
ATXN3L were iden t i f i ed in some ALS pat ien t s
(Supplementary Table 1) [110]. ATXN1 encodes a protein
mainly implicated in mRNA processing (Table 2 and Fig. 4)
that normally contains a polyglutamine (polyQ) tract with 22–
23 repeats; the occurrence of an expanded polyQ repeat has
been associated with an increased genetic risk for ALS [122].
In addition to structural aberration, decreased expression of
ATXN1 was recently found in a specific subgroup of SALS
patients [52]. ATXN1 seems also to be involved in transcrip-
tional repression of angiogenic factors whose deregulations
were widely associated with ALS pathogenesis [123].
Another gene involved in the regulation of angiogenic signal-
ing pathway is BAIAP2, a gene encoding a brain-specific an-
giogenesis inhibitor that is able to modulate synaptic transmis-
sion as well as learning and memory (Table 2 and Fig. 4)
[124]. Segmental copy number gains in BAIAP2 and other
structurally related genes (e.g., BAIAP3), were found in some
cases of ALS patients (Table 1) [110, 111]. In addition, in-
creased expression of BAIAP2 and BAIAP3 was found in mo-
tor cortex of SALS patients, supporting the theory that an
excessive angiogenesis may contribute to ALS pathogenesis.
Copy number gains in CPLX1 have been identified at a
significantly higher frequency in ALS patients compared to
controls (Table 1) [110].CPLX1 encodes a protein involved in
synaptic vesicle exocytosis whose deregulation has been im-
plicated in the pathogenesis of several neurological and neu-
rodegenerative diseases, including ALS (Table 2 and Fig. 4)
[52, 125].
Transcriptional Regulation
Mounting evidence has emerged to support an important role
of transcription dysregulation in the initiation and progression
of several neurodegenerative diseases, including ALS. Indeed,
widespread aberrations in the molecular machinery that
regulate gene expression and mRNA splicing have been re-
ported both in sporadic and familial forms of ALS [126, 127].
Although the mechanisms and causal relationships have not
yet been fully elucidated, several genome-wide studies have
identified ALS-linked mutations and ALS-specific copy num-
ber variations in genes involved in the regulation of RNA
processing and, thus, in the control of gene expression. In
particular, the deletion of an intron of ZFP14 was found in
two ALS patients but not in individual controls (Table 1)
[111]. The functional group of ZFP14 proteins exerts diverse
functions, many of which have been extensively implicated in
ALS, such as RNA packaging, transcriptional activation, reg-
ulation of apoptosis, as well as protein folding and assembly
(Table 2 and Fig. 4).
A large deletion affecting GEMIN6, another gene involved
in the control of neuronal gene expression, was found in a
single ALS patient (Supplementary Table 1). GEMIN6 is
mainly implicated in the regulation of mRNA processing
and belongs to the SMN complex, which as previously
discussed is a potential risk factor in ALS susceptibility
(Table 2 and Fig. 4). In particular, a reduced expression of
GEMIN6 has been associated with a reduced activity of the
SMN complex, contributing to alter normal snRNP assembly
and leading to motor neuron degeneration [128].
A process that has been directly implicated in genetic
causes of various motor neuron diseases is the enzymatic de-
livery of aminoacyl transfer RNAs (tRNAs) to the ribosome.
Among genes involved in this process is EEF1D, a gene
encoding a subunit of the elongation factor-1 complex. Copy
number gains and losses in EEF1D were found in a modest
number of ALS patients and increased expression of EEF1D
was recently found in SALS patients, confirming the potential
role of this factor in ALS pathogenesis (Tables 1 and 2 and
Fig. 4) [52, 110].
Immune Response and Inflammation
Immune processes inside the central nervous system contrib-
ute to the maintenance of homeostasis and play important
roles in resolving inflammation and mediating neuroprotec-
tion and repair [129]. Immune responses are finely regulated
by multiple checkpoints that are responsible to ensure the
protection of neuronal tissue from harmful events.
There is strong evidence that the acute neuroinflammation
and the dysregulated immune response are potentially patho-
genic factors in a number of neurodegenerative diseases, in-
cluding ALS [130]. To this regard, aberrant gene expression
and copy number variations in genes involved in neuroinflam-
mation and cellular response to injurious stimuli (FOXO3,
HFE, GSDMD) have been identified in ALS patients with
respect to controls (Table 1 and Supplementary Table 1) [99,
110, 117]. In particular, FOXO3 encodes a transcription factor
involved in apoptosis, cellular metabolism, and resistance to
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oxidative stress, while variations in HFE, a gene encoding a
protein involved in antigen presentation and processing, have
been reported to significantly increase the risk of SALS in a
number of different individuals (Table 2 and Fig. 4) [52, 131,
132]. ALS-specific copy number gains and losses were found
also in a genomic region encompassing GSDMD, a gene
encoding a member of the gasdermin family that appears to
play a role in neuroinflammatory and caspase-induced apo-
ptotic processes (Tables 1 and 2 and Fig. 4).
Signal Transduction
Signal transduction refers to the process through which an ex-
tracellular biological molecule, by interating with specific
cell-surface receptors, activates a biochemical chain of events
inside the cell, eventually eliciting a response. Neuron-specific
alterations in various signal transduction pathways represent
one of the principal pathological hallmarks of several neurolog-
ical diseases, including ALS [133, 134]. An elevated number of
genes encoding several trophic factors and their receptors as
well as proteins involved in the regulation of intracellular sig-
naling cascades were found differentially expressed in SALS
motor cortex [52]. In addition, rare copy number aberrations in
genes involved in multiple signaling cascades (IGFALS,
SPSB3, FOXO3 and FMN2) were also found in some cases
of ALS, suggesting that alterations in these genes, either alone
or in combination, may concur to generate motor neuron injury
in ALS.
IGFALS encodes a serum protein that binds insulin-like
growth factors (IGFs), increasing their half-life and their vas-
cular localization. Increased expression of genes encoding
IGF receptors and IGFALS was found in motor cortex of
SALS patients [52]. In addition, structural gains in the geno-
mic region encompassing IGFALS gene were identified in
some ALS cases, supporting the hypothesis that dysregulation
of this signaling cascade may be critical for ALS pathogenesis
(Tables 1 and 2 and Fig. 4) [110, 135]. It has been also ob-
served that pharmacological inhibition of the IGF signaling
pathway exerts neuroprotective effects in different models of
neurodegeneration [136]. In addition to IGFALS, another gene
involved in the regulation of the intracellular signal transduc-
tion maps within the region of gain at chromosome 16
(Tables 1 and 2 and Fig. 4) [110]. This is SPSB3, a gene
encoding a protein involved in the ubiquitine-proteasome
pathway, the major proteolytic quality control system in cells,
whose deregulation has been associated with numerous neu-
rodegenerative diseases, like ALS, leading to abnormal pro-
tein aggregation and consequent neuron death [137].
Several GWAS studies have confirmed the presence of a
homozygous deletion affecting an intron of FMN2 gene in
some cases of ALS but not in controls (Table 1) [80, 110,
138]. FMN2 is expressed in brain and spinal cord and plays
an important role in the regulation of cytoskeletal assembly,
signal transduction, and protein transport (Table 2 and Fig. 4).
Decreased expression of this gene has been related to age-
dependent memory loss in mice and SNPs in this gene have
been detected in SALS patients [139, 140].
Metabolic Homeostasis
Maintaining a metabolic homoeostasis requires a balance be-
tween energy intake and expenditure. Growing evidence high-
lights that an imbalance in energy metabolism may contribute
to the selective death of neurons in ALS [141]. To this regard,
copy number abnormalities in some genes involved in meta-
bolic processes (IGFALS, UBE2I, ACYP2, MTMR7) have
shown to be potential risk factors for ALS (Table 1 and
Supplementary Table 1). In particular, a structural gain on
chromosome 16 encompassing multiple genes potentially in-
volved in ALS, including UBE2I, was found in a moderate
number of ALS patients (Table 1) [110]. UBE2I encodes an
ub iqu i t i n - con juga t ing enzyme invo lved in the
ubiquitin-proteasome system that is crucial to a vast array of
cellular processes, such as cell cycle control, immune re-
sponses, and metabolic regulation [142]. Recently, an upreg-
ulated expression of UBE2I was identified in astrocytes from
ALS animal models and a differentially expression of its gene
was also found in motor cortex of SALS patients [52, 143,
144].
Heterozygous deletions ofMTMR7 and ACYP2 genes were
found in a limited number of ALS patients, but not in controls
or DGV (Supplementary Table 1) [84, 96, 145]. MTMR7 is
expressed specifically in the brain and is involved in the lipid
metabolism and phosphatidylinositol signaling pathway, a
mechanism implicated in ALS pathogenesis (Table 2 and
Fig. 4) [146]. ACYP2 encodes a protein belonging to enzyme
family that acts as a phosphatase and is implicated in meta-
bolic processes and Ca+2 modulation (Table 2 and Fig. 4).
Interestingly, deletions of ACYP2 have been associated with
a relatively early age of disease onset (32–44) in ALS patients,
and its reduced expression has been found in the motor cortex
of SALS patients [52].
Another interesting heterozygous deletion encompassing
GGTLC2 was found significantly higher in controls as com-
pared to ALS patients, suggesting a potential protective role of
this variant against the risk of developing ALS (Table 1).
GGTLC2, whose decreased expression was found in SALS
patients [52], encodes a protein involved in glutathione me-
tabolism, a process associated with altered energy metabolism
in ALS pathogenesis (Table 2 and Fig. 4) [147, 148].
Apoptosis
Apoptosis is a type of programmed cell death that plays an
essential role during embryogenesis, cellular homeostasis, im-
mune system maturation, and cellular response to external
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stimulus, including DNA damage and oxidative stress. There
is strong evidence to suggest that apoptosis is responsible for
motor neuron degeneration in ALS [149]. Apart from genetic
mutations and changes in gene expression, copy number ab-
errations in genes encoding factors involved in the control of
apoptosis were detected only in ALS patients and absent in
controls, suggesting a possible contribution of these variants
in increased risk of developing ALS (Table 1 and
Supplementary Table 1). In particular, heterozygous deletions
in regions encompassing ATG7, ANXA5, and PPP1R13B
genes and a segmental gain in the AATK gene were observed
(Table 1 and Supplementary Table 1) [111, 138, 145]. ATG7 is
a crucial factor for the induction of autophagy and
ubiquitin-related activities as well as in apoptosis and the
maintenance of axonal homeostasis (Table 2 and Fig. 4)
[150]. Interestingly, deletions of ATG7 have been reported to
induce axonal degeneration in a mouse model, leading to ac-
cumulation of polyubiquitinated aggregates and severe neuro-
degeneration. ANXA5 encodes a protein that plays an essential
role in apoptosis and survival as well as neurite growth of
in vitro cortical neurons and has been previously indicated
as a candidate gene for ALS (Table 2 and Fig. 4) [151, 152].
PPP1R13B encodes an apoptosis-stimulating protein that is
able to interact with p53, regulating neuronal differentiation
and specifically enhancing p53-induced apoptosis that was
identified as an apoptotic mode of motor neuron cell death
in the spinal cord of ALS patients (Table 2, Fig. 4, and
Supplementary Table 1) [153–155]. AATK encodes a protein
that plays an essential role in the induction of mature neuron
apoptosis, neuronal genesis and differentiation, as well as ax-
on outgrowth. Copy number gains in AATK are in accordance
with the evidence that an increased expression of this gene is
induced during apoptosis, supporting a role of this signaling
pathway in ALS (Table 2 and Fig. 4) [156].
Neuronal Development and Differentiation
Neuronal development is a process strongly dependent from a
balanced and tightly regulated control of several trophic fac-
tors capable of regulating important physiological processes,
including neuronal survival, migration, and differentiation as
well as synapse and dendrite maintenance and axonal out-
growth [157]. Alterations to crucial genes regulating neural
development and differentiation can lead to impairments in
the cellular homeostasis and have been associatedwith numer-
ous neurodegenerative diseases, such as Huntington’s and
ALS [158, 159]. In addition to changes in genetic and epige-
netics factors, through mutation or altered gene expression,
copy number variations were associated as potential risk fac-
tors for ALS also. In fact, segmental duplications in genes
involved in the regulation of neuronal cell death and differen-
tiation (FOXO3, ANKRD11,MAPK8IP3) were found in some
cases of ALS (Table 1).
ANKRD11 is a large nuclear protein that regulates transcrip-
tion, potentially by binding chromatin-modifying enzymes and is
involved in apoptotic processes by enhancing the transcriptional
activity of p53 proteins (Table 2, Fig. 4 and Supplementary
Table 1) [153, 154]. A structural gain in an intron of
ANKRD11 was identified only in two ALS patients compared
to control subjects [99] (Table 1). In addition to structural aber-
rations, mutations and altered expression of ANKRD11 have
been associated with perturbations in neural development occur-
ring in some neurological conditions, such as autism [160].
MAPK8IP3 encodes a protein that binds and regulates the
activity of numerous protein kinase components of the c-Jun
N-terminal kinase (JNK) signaling pathway, facilitating JNK
activation and thus playing a role in the regulation of many
cellular events, including growth control, apoptosis, and axo-
nal transport [161]. Increased levels ofMAPK8IP3 seem to be
required for neurodegeneration in different models of neuro-
logical disorders, including Parkinson’s and Alzheimer’s dis-
eases, suggesting that accumulations of these proteins may
represent a response to oxidative stress conditions [162, 163].
Neuronal Transport
The trafficking and transport of vital cellular components is crit-
ical for correct neuronal function and axonal maintenance.
Increasing evidence has highlighted a correlation between dys-
function of the cellular transport machinery, for example caused
by an oxidative damage, and many neurodegenerative condi-
tions, including ALS [164]. Besides point mutations in genes
extensively related to ALS pathophysiology (e.g., C9orf72,
TDP-43, VAPB, DCTN1), several copy number aberrations
encompassing genes involved in the regulation of neuronal trans-
port were found in ALS patients. In addition to some genes that
were previously discussed in the above paragraphs (ATG7,
NIPA1, CACNA1H, KCNIP4, KCNQ5, KCNB2, SLC1A7,
CO3, MAPK8IP3, ANXA5, HFE, FMN2, NEFH, EPHA3),
two interesting segmental duplications in TRDN and CHMP6
were found in some cases of ALS and in none of patient controls
(Supplementary Table 1) [84, 138, 165]. TRDN encodes an inte-
gral membrane protein highly expressed in skeletal muscle with
a recognized role in calcium release, and whose low expression
has been found in brain and nerve tissue, suggesting its potential
role in motor neuron diseases (Table 2, Fig. 4, and
Supplementary Table 1) [166]. CHMP6 encodes a member of
CHMP subfamilies involved in the formation of endocytic
multivesicular bodies that are required for autophagic clearance
of protein aggregates (Table 2 and Fig. 4). Deregulation in this
process leads to abnormal ubiquitin-positive protein deposits in
neurons that represent a hallmark of several neurodegenerative
diseases, including ALS. In addition, mutations in another com-
ponent of CHMP family (CHMP2B) have been widely implicat-
ed in frontotemporal dementia and ALS [167], sustaining the
role of this protein family in ALS pathogenesis.
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Rare ALS-Related CNVs in Intergenic Regions
In addition to CNVs overlapping with genes, several rare
non-polymorphic structural variants overlapping with pro-
moters or intergenic regions have been reported as potential
ALS candidate CNVs. Although these regions are difficult to
decode, the possibility of long-acting gene regulatory zones
residing in these regions cannot yet be excluded. Among
these, of particular interest are two heterozygous deletions
affecting intergenic regions of chromosome 11, in the prox-
imity of the centromere, and chromosome 19 (Table 1) [96].
Despite CNVs overlapping, telomeric and centromeric chro-
mosome regions should be treated with more caution because
of the lower probe density coverage that makes them more
prone to false CNV calls than other regions of the genome, a
significant association was found between CNVs in these re-
gions and an increased risk of developing ALS (Table 1).
Several interesting CNV-driven genomic regions
encompassing the promoter region of RPS3A, DHX30,
UGT8 and CHL1 were also found in ALS patients (Table 1)
[138]. RPS3A encodes a ribosomal protein that plays roles in
regulating cell growth, transformation and death. DHX30 en-
codes an RNA helicase that is thought to be an accessory
subunit of the mitochondrial ribosome and whose depletion
has been associated with alterations in the levels of mitochon-
drial mRNAs [168, 169]. UGT8 is a protein belonging to a
glycosyltransferase family involved in lipid biosynthesis and
metabolism, a process implicated in ALS pathogenesis. CHL1
is a neural cell adhesion molecule that plays a crucial role in
axonal guidance and maintenance of neural circuits [170].
Other ALS-related CNVs were found in regions of chromo-
somes 5, 8, and 11 flanking HCN1, POTEA, OR4A5, and
OR4C12, respectively (Table 1) [138]. HCN1 encodes a major
component of the hyperpolarization-activated cyclic
nucleotide-gated channels that seems to enhance
hippocampal-dependent learning and memory and modulate
synaptic transmission and plasticity [171]. Duplications in
POTEA have been already reported in some cases of early onset
Alzheimer’s disease [172]. Olfactory receptor genes (e.g.,
OR4A5 andOR4C12) have been directly or indirectly involved
in neuronal injury and nerve regeneration, and their dysregula-
tion was associated with several neurodegenerative conditions,
like Alzheimer’s and Parkinson’s diseases [173, 174].
Conclusions
Despite intensive researches and incredible technological ad-
vancements, ALS still remains a fatal incurable neurodegen-
erative disease in which the majority of cases are diagnosed in
advanced stages with limited treatment options and poor prog-
nosis. The most important challenges in the clinical manage-
ment of ALS are the better understanding of causes and
mechanisms underlying motor neuron degeneration as well
as the identification of precise diagnostic biomarkers and ef-
fective therapeutic strategies.
To achieve a comprehensive understanding of the complex
genetic-environmental interactions underlying ALS suscepti-
bility, all forms of genetic variation need to be addressed. In
addition to the contribution of SNPs, which account for only a
limited number of familial and sporadic ALS cases, evidence
suggests that other genomic variants, such as CNVs, appear to
have amore dramatic impact on human disease phenotype and
represent important clues for the deciphering genetic suscep-
tibility to complex diseases, like ALS. However, the tradition-
al single-gene analysis generally accounts for only a small
proportion of the phenotypic variation in ALS while is often
inadequate for evaluating the collective effects of multiple rare
CNVs on disease risk.
The systems biology paradigm represents an innovative
way for analyzing the complex underlying biological process-
es, providing new instruments to fill interstices of the intricate
mosaic of ALS pathogenesis and generate a more definite
molecular picture of this disease.
Here, we provided some insights into the associations be-
tween common and rare CNVs and ALS pathogenesis, focus-
ing on the characterization of the potential CNVs’ impact on
different signaling pathways whose deregulation seems to
contribute to motor neuron degeneration in ALS. Overall,
the use of this integrative genomics approach promises to
enlarge our knowledge about genetic and molecular risk fac-
tors for ALS and, even in the light of the molecular heteroge-
neity emerged from our previous work [52], offers an impor-
tant stepping-stone for the understanding, diagnosis and treat-
ment of complex and multifactorial diseases, like ALS.
We believe that future comprehensive analyses of structural
genomic variations together with other high-resolution
genotyping data, could help to provide a better definition of
the molecular signatures of ALS, laying the basis for a more
accurate and precise molecular biomarker-assisted diagnosis
and the ultimate development of more effective and personal-
ized therapeutic strategies (Fig. 2).
Cu/Zn superoxide-dismutase gene (SOD1); alsin (ALS2);
senataxin (SETX); spastic paraplegia type 11 (SPG11); FUS
RNA binding protein (FUS); vesicle-associated protein B
(VAPB); angiogenin (ANG); TAR DNA binding protein
(TARDBP); FIG4 phosphoinositide 5-phosphatas (FIG4);
optineurin (OPTN); ataxin 2 (ATXN2); ubiquilin 2
(UBQLN2); granulin (PGRN); profilin 1 (PFN1); dynactin 1
(DCTN1); chromosome 9 open reading frame 72 (C9ORF72);
vascular endothelial growth factor A (VEGFA); FGGY carbo-
h y d r a t e k i n a s e d oma i n c o n t a i n i n g ( FGGY ) ;
dipeptidyl-peptidase like 6 (DPP6); inositol 1,4,5-trisphosphate
receptor type 2 (ITPR2); kinesin associated protein 3 (KIFAP3);
unc-13 homolog A (UNC13A); apoptosis-associated tyrosine
kinase (AATK); brain-specific angiogenesis inhibitor
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1-associated protein 2 (BAIAP2); charged multivesicular body
protein 6 (CHMP6); insulin-like growth factor binding protein
acid labi le subuni t ( IGFALS); calcium channel ,
voltage-dependent, T type, alpha 1H subunit (CACNA1H);
mitogen-activated protein kinase 8 interacting protein 3
(MAPK8IP3); BAI1-associated protein 3 (BAIAP3);
ubiquitin-conjugating enzyme E2I (UBE2I); splA/ryanodine re-
ceptor domain and SOCS box containing 3 (SPSB3); Kv chan-
nel interacting protein 4 (KCNIP4); potassium channel, voltage
gated Shab related subfamily B; member 2 (KCNB2); potassi-
um channel, voltage gated KQT-like subfamily Q, member 5
(KCNQ5); gasdermin D (GSDMD); glutamate receptor,
ionotropic, kainate 1 (GRIK1); glutamate receptor, ionotropic,
kainate 2 (GRIK2); eukaryotic translation elongation factor 1
delta (EEF1D); ataxin 1 (ATXN1); ataxin 3-like protein
(ATXN3L); solute carrier family 1 member 7 (SLC1A7); triadin
(TRDN); complexin-1 (CPLX1); ankyrin repeat domain 11
(ANKRD11); protein phosphatase 1 regulatory subunit 13B
(PPP1R13B); forkhead box O3 (FOXO3); hemochromatosis
(HFE); gamma-glutamyltransferase light chain 2 (GGTLC2);
autophagy related 7 (ATG7); annexin A5 (ANXA5); gem-
associated protein 6 (GEMIN6); myotubularin related protein
7 (MTMR7); acylphosphatase 2 (ACYP2); ZFP14 Zinc Finger
Protein (ZFP14); formin 2 (FMN2); ribosomal protein S3A
(RPS3A); DEAH-box helicase 30 (DHX30); UDP glycosyl-
transferase 8 (UGT8); cell adhesion molecule L1 like (CHL1);
hyperpolarization-activated cyclic nucleotide-gated channel 1
(HCN1); POTE ankyrin domain family member A (POTEA);
olfactory receptor family 4 subfamily A member 5 (OR4A5);
olfactory receptor family 4 subfamily C member 12 (OR4C12);
NADH dehydrogenase subunit 2 (ND2); cytochrome oxidase
subunit-3 (CO3); NADH dehydrogenase subunit 4 (ND4).
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